MLTX

MOONLAKE IMMUNOTHERAPEUTICS

MLTX·61559X104·US·Common Stock·Healthcare - Biotechnology-Activist

CLASS A ORD

MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is held by 81 institutional investors as of Q1 2026. Largest holders: Janus Henderson Group Ltd. ($64.3M), D. E. Shaw & Co., Inc. ($44.6M), Point72 Asset Management, L.P. ($25.5M). Net institutional sentiment: Mixed.

81
Holders
(4 Elite)
$436.6M
Total Value
57% (82)
Consensus
47 buying - 35 selling
13F: Insider & Congress:
MLTXSmart Money Verdict
View all
Held by 81 funds
4 elite
Who's Trading
InsiderSJSantos da Silva JorgeSell $1.4MJul 10, 2026
InsiderSJSantos da Silva JorgeSell $679KJul 9, 2026
ActivistBVBIOTECHNOLOGY VALUE FUND L P10.2%Jun 29, 2026
ActivistCACormorant Asset Management, LP6.3%May 15, 2026
InsiderBMBodenstedt MatthiasSell $273KMay 11, 2026
InsiderBMBodenstedt MatthiasSell $47KApr 14, 2026
InsiderSJSantos da Silva JorgeSell $946KApr 13, 2026
InsiderSJSantos da Silva JorgeSell $1.8MApr 10, 2026
InsiderBMBodenstedt MatthiasSell $38KApr 10, 2026
InsiderBMBodenstedt MatthiasSell $1.6MApr 9, 2026
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
3.5M(+64.7%)$64.3M0.0%+34.74%
43
Decreased
2.4M(-3.6%)$44.6M0.0%+54.13%
0
Increased
1.4M(+77.2%)$25.5M0.0%+32.15%
43
Increased
1.3M(+247.5%)$24.7M0.0%+23.16%
46
Increased
1.3M(+34.9%)$24.1M0.0%-37.29%
37
Increased
1.1M(+317.6%)$21.1M0.0%-22.14%
46
Increased
1.1M(+43.0%)$20.9M0.0%+73.48%
38
Decreased
1.1M(-32.2%)$19.9M0.0%+22.07%
0
Increased
1M(+256.6%)$19M0.0%-4.11%
46
Increased
1.1M(+29.9%)$18.4M0.0%+39.21%
36
Increased
818,126(+509.1%)$15.2M0.1%-16.17%
45
Increased
724,794(+5255.8%)$13.5M0.0%+14.93%
45
Decreased
614,482(-41.2%)$11.5M0.0%+55.08%
0
New
600,000$11.2M0.0%+15.09%
38
Decreased
576,092(-28.2%)$10.7M0.0%+63.72%
0
Unchanged
500,000$9.3M0.1%+53.13%
0
Increased
495,336(+168.7%)$9.2M0.1%+27.07%
45
Decreased
453,625(-73.0%)$8.5M0.0%+55.20%
0
Decreased
341,424(-37.8%)$6.4M0.0%+89.59%
0
Increased
320,472(+323.1%)$6M0.0%+22.42%
44

Showing 1-20 of 89

1 / 5

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used